This study is looking at how well ciprofloxacin (500 mg, taken once orally) works to treat Neisseria gonorrhoeae (a sexually transmitted infection, also called Ng or gonorrhea). Researchers want to see if using a special test called the SpeeDx Resistance Plus assay, which checks for a specific gene change (gyrA mutation) in the bacteria, can help decide if ciprofloxacin will be an effective treatment. You might be able to join if you are 18 or older, speak English, have internet access, and are getting routine STI screening without active symptoms. The study aims to see how many people with a specific type of Ng infection (gyrA wildtype) are cured with ciprofloxacin over two years. The study plans to enroll 1800 people and its current status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 1800 participants.

What's involved

You will have specimens collected from areas of exposure for testing. If you are N. gonorrhoeae positive and have the gyrA wildtype, you will receive ciprofloxacin 500 mg orally once.

Compensation

Not stated in the trial record.

Follow-up

The effectiveness of the treatment will be measured at 2 years after receiving ciprofloxacin.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.